Also known as: BeOne Medicines
BeOne Medicines is a global oncology company developing and delivering cancer medicines across multiple markets. Founded in 2010 and now based in Basel, it operates as a publicly listed company with broad international R&D and commercialization activity.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07590102 |
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07554521 |
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States |
RECRUITING | PHASE2 |
| NCT07492641 |
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease |
RECRUITING | PHASE3 |
| NCT07485049 |
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors |
RECRUITING | EARLY_PHASE1 |
| NCT07414836 |
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07341191 |
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy |
RECRUITING | PHASE2 |
| NCT07277231 |
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia |
RECRUITING | PHASE3 |
| NCT07226349 |
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07222267 |
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07181681 |
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
